Rosutor

Therapeutic Segment:
Anti-lipidemic

Generic Name:
Rosuvastatin

Description:
Rosutor (Rosuvastatin), a synthetic lipid-lowering agent for oral administration. Rosuvastatin Calcium is bis[(E)-7-[4-(4-flurophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amin o]pyrimidin-5 yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt. The molecular formula for Rosuvastatin Calcium is (C22H27FN3O6S)2Ca.

Indication:

Rosutor (Rosuvastatin) is indicated for the treatment of: 1. Hyperlipidemia and mixed Dislipidemia: As Adjunctive therapy to diet to reduce elevated Total-C, LDL-C ApoB, nonHDL-C and triglycerides and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia Lipid altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and nonpharmacological interventions alone has been inadequate. 2. Pediatric Patients 10 to 17 years of age with Heterozygous Familal Hypercholesterolemia (HeFH): Adjunct to diet to reduce Total-C, LDL-C and ApoB levels in adolescent boys and girls, who are at least one year postmenarche, 10-17 years of age with heterozygous familial hyperchlosterolemia if after an adequate trial of diet theraphy the following findings are present: LDL-C greater than 190 mg/dL or greater than 160 mg/dL and there is a positive family history premature cardiovascular disease (CVD) or two or more other CVD risk factors. 3. Hypertriglyceridemia: As Adjunctive theraphy to diet for the treatment of adult patients with hypertriglyceridemia. 4.Primary Dysbetalipoproteinemia: (Type III Hyperlipoproteinemia) As as adjunct to diet for the treatment of patients with primary dysbetalipoproteinemia (Type III Hyperlipoproteinemia.) 5. Homozygous Familal Hypercholesterolemia: As Adjunctive theraphy to other lipid lowering treatments (e.g., LDL apheresis) or alone if such treatments are unavailable to reduce LDL-C. Total-C, and ApoB in adult patients with homozygous familial hypercholesterolemia. 6.Slowing of the Progression of Atherosclerosis: As adjunctive therapy to diet to slow the progression of atherosclerosis in adult patients as part of a treatment strategy to lower Total-C and LDL-C to target levels. 7. Prevention of Cardiovascular Events: Prevention of major cardiovascular events in patients who are estimated to have a high risk for a first cardiovascular event, as an adjunct to correction of other risk factors.

Formulation:

• Tablets

Strength:

•  10mg
• 20mg

Pack Size:

• 1 x 14s